High-Sensitivity Cardiac Troponin-I Is Elevated in Patients with Rheumatoid Arthritis, Independent of Cardiovascular Risk Factors and Inflammation

William S. Bradham, Vanderbilt University
Aihua Bian, Vanderbilt University
Annette Oeser, Vanderbilt University
Tebeb Gebretsadik, Vanderbilt University
Ayumi Shintani, Vanderbilt University
Joseph Solus, Vanderbilt University
Joel Estis, Singulex Inc
Anh Lu Quynh, Singulex Inc
John Todd, Singulex Inc
Paolo Raggi, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: PLoS ONE
Volume: Volume 7, Number 6
Publisher: Public Library of Science | 2012-06-28, Pages e38930-e38930
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1371/journal.pone.0038930
Permanent URL: https://pid.emory.edu/ark:/25593/s5j36

Final published version: http://dx.doi.org/10.1371/journal.pone.0038930

Copyright information:
© 2012 Bradham et al.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed January 24, 2020 3:14 AM EST
Introduction

Patients with rheumatoid arthritis (RA) experience premature mortality that is largely due to cardiovascular disease [1,2]. Cardiovascular mortality in RA is 50–60% higher compared to the general population, and there is increased prevalence of ischemic heart disease [3-6]. There is a markedly higher prevalence of congestive heart failure (CHF) in RA patients. For example, in a longitudinal, population-based study, the 30-year cumulative incidence of CHF in RA was 37.1% compared to 27.7% in controls, and CHF, rather than ischemic heart disease, accounted for the majority of the increase in cardiovascular mortality in RA [7].

We have previously reported increased concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with RA [8]. NT-proBNP is released by myocytes in response to myocardial stretch, and subtle increases may reflect subclinical myocardial dysfunction [9]. Cardiac magnetic resonance imaging has demonstrated decreased left ventricular mass in patients with RA [10]. Thus, RA may predispose to the development of heart failure through a pathophysiology distinct from that of ischemic...
heart disease; and chronic, indolent myocyte loss may be a central process.

Cardiac troponins (cTn) are components of the cardiomyocyte contractile apparatus, and circulating concentrations are elevated in the setting of myocardial injury, such as acute coronary syndromes (ACS) [11]. High-sensitivity (hs) cTn assays allow measurement of troponin concentrations below conventional levels of detection and have revealed a spectrum of circulating cTn concentrations spanning low and high levels in both healthy subjects and in patients with overt cardiovascular disease. Low levels of troponin elevation, below threshold levels used to diagnose ACS, are associated with increased CV mortality, both in patients with diagnosed ischemic heart disease and in the general population [12,13].

There is no information about cardiac troponin concentrations in patients with RA. We hypothesized that concentrations high sensitivity cardiac troponin (hs-cTn), a marker of myocyte injury, may be elevated early in the disease process, before the development of clinical heart failure.

Methods

Ethics Statement

The study was approved by the Institutional Review Board (IRB) of Vanderbilt University Medical Center, and all subjects were provided written informed consent.

Patients and Control Subjects

Subjects were participants in an ongoing study of cardiovascular risk in RA, and detailed methods have been described previously [14,15]. One hundred and sixty four eligible patients >18 years of age who met the American College of Rheumatology classification for RA and 90 control subjects without RA were studied. Individuals with heart failure, defined as current heart failure requiring treatment, or fulfillment of at least 2 of three following criteria; a previous history of heart failure, use of digoxin, or use of a diuretic, were excluded from the study.

Patients were recruited from an RA registry, by referral from area rheumatologists, and by local advertisement. Control subjects were recruited from among the patient’s acquaintances, by local advertisement, and from a database of volunteers maintained by the Vanderbilt Clinical Research Center.

Data Collection

Clinical and demographic information was acquired via structured interview, questionnaires, physical examination, laboratory tests, electron beam computed tomography (CT), and review of medical records. Current and historic medication use was determined from information provided by patients, and from review of medical records. Blood pressure was recorded as the average of 2 measurements obtained 5 minutes apart after the subject had rested in a supine position for at least 10 minutes. Subjects were considered hypertensive if they were taking antihypertensive agents, or if measured systolic blood pressure was greater than 140 mm Hg and/or diastolic pressure was greater than 90 mm Hg. RA disease activity was assessed using the Disease Activity Score based on evaluation of 28 joints (DAS28). The DAS28 is a validated composite index including a 28 joint count for tenderness and swelling, erythrocyte sedimentation rate (ESR), and the patient’s overall assessment of wellbeing [16]. The Framingham risk score (FRS), a composite score of traditional risk factors that includes blood pressure, smoking status, age, and sex, but not diabetes mellitus, was calculated.

Laboratory Tests

Blood was collected after an overnight fast for determination of complete blood count, serum creatinine, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, homocysteine, and low-density (LDL) cholesterol at the Vanderbilt University Medical Center clinical laboratory. In patients with RA, CRP and Westergren ESR were measured by the hospital laboratory, and medical records reviewed to determine the presence or absence of rheumatoid factor (RF). Before 2003, the laboratory did not use a high-sensitivity CRP assay, and low concentrations were reported as <3 mg/L. Thus, in 40 patients with CRP reported as <3 mg/L, concentrations were re-measured by ELISA (Millipore), and the resulting data were used in the current study analysis. High sensitivity cardiac specific troponin-I (hs-cTn-I) was assayed using the Erenna® System (Singulex Corp, Alameda, CA) by technicians blinded to the clinical data. The limit of detection and the 10% coefficient of variation were 0.1 pg/mL and 0.7 pg/mL, respectively. TNFα, interleukin-6 (IL-6), and NT-pro-BNP concentrations were measured by multiplex enzyme-linked immunosorbent assay (Linco Research/Millipore, St. Louis, MO).

Coronary Artery Calcification

All subjects underwent tomographic imaging with a c-150 scanner (GE/Imatron, South San Francisco, CA) as described previously [14]. Scans were evaluated by a single investigator blinded to patient clinical status. The degree of calcified plaque was calculated as described previously; the sum of partial scores of all coronary artery lesions provided an overall coronary artery calcium score (CACS) for each patient [15].

Statistical Analysis

Descriptive statistics were calculated as the median with the interquartile range (median [IQR]) or mean ± SD according to the distribution of the continuous variables. Wilcoxon rank-sum tests were used to compare continuous variables. Person Chi-square tests were used to compare categorical variables. We assessed the correlation between hs-cTn-I concentration and cardiovascular risk factors (body mass index (BMI), high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol, triglycerides (TG), diabetic status, homocysteine, lipoprotein(a), inflammation markers (CRP, IL-6 and TNFα) with Spearman’s rank correlation test separately for patients with RA and control subjects. To assess the independent association between RA status and hs-cTn-I concentration, we used 4 multivariable linear regression models with a priori defined covariates. Those models adjusted for:

- **Model 1.** Age, race, and sex (base model);
- **Model 2.** Base model and cardiovascular risk factors (body mass index (BMI), high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol, triglycerides (TG), diabetic status, homocysteine, lipoprotein(a), current smoking status, and hypertension (HTN));
- **Model 3.** Base model and markers of inflammation (C reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNFα); and
- **Model 4.** Base model, cardiovascular risk factors (as in Model 2), markers of inflammation (as in Model 3), and NT-proBNP.

Among the RA group, the association between hs-cTn-I concentrations and CACS was examined using the proportional odds model with CACS as the dependent variable, and were adjusted for age, race, sex, and FRS. Concentrations of hs-cTn-I, triglycerides, homocysteine, CRP, TNF-α, and IL-6 were natural logarithm-transformed to improved normality. All calculations were performed using R version 2.10.0 (http://www.r-project.org).
and two-sided P values less than 0.05 were considered statistically significant.

Sensitivity Analysis for Possible Confounders

Because cardiac troponin is renally cleared, the results of the study could be confounded in patients with poor renal function. To account for renal function, the statistical models were analyzed by including the estimated glomerular filtration rate (Modification of Diet in Renal Disease calculation) in the model. Further, to control for the presence of known cardiovascular disease in the study subjects, the statistical models were re-analyzed, excluding patients with a diagnosed cardiovascular disease (22 RA patients, 8 control patients excluded).

Results

Patient Characteristics

Patients with RA (n = 164) and control subjects (n = 90) were of similar age and had a similar sex distribution (Table 1). As reported previously in this cohort, NT-BNP, CRP, TNFa, IL-6, homocysteine, and CACS were significantly higher in RA than in control subjects [9,14,15]. A history of ischemic cardiovascular disease (stroke, myocardial infarction, angina) or a coronary procedure (coronary artery bypass graft or angioplasty) was present in 13% of patients with RA and 9% of controls (P = 0.29).

High Sensitivity cTn-I Concentrations and Clinical Variables in RA Patients and Controls

High sensitivity cTn-I concentrations were significantly higher in patients with RA (median 1.15 pg/mL [IQR 0.73–1.92] than controls (0.77 pg/mL [0.49–1.28]) [P<0.001] (Figure 1). Hs cTn-I remained significantly higher in RA patients after adjustment for age, race, and sex [p = 0.002] (Figure 2- Model 1); age, race, sex and cardiovascular risk factors [p = 0.004] (Figure 2- Model 2); age, race, sex, and markers of inflammation [p = 0.008] (Figure 2- Model 3); and age, race, sex, GV risk factors, markers of inflammation, and NT-proBNP [p = 0.029] (Figure 2- Model 4). Rheumatoid factor was measured...
in 157 patients, and hs-cTn-I concentrations were not significantly different among RA patients in whom rheumatoid factor was present (1.17 [0.73–1.99] pg/ml, n = 112 (71%)), or absent (1.09 [0.73–1.41] pg/ml, n = 45 (29%))(p = 0.28).

Sensitivity Analysis
Sensitivity analyses were performed adjusting for renal function (MDRD) and excluding study subjects with previous CV disease. The finding that hs-cTn-I was higher in RA patients compared to controls remained statistically significant in models 1–4 (all P values <0.05).

Association between hs-cTn-I Concentrations and Clinical Variables
In RA, hs-cTn-I concentrations were positively correlated with age, systolic BP, CACS and NT-proBNP; and in control subjects with systolic BP, serum creatinine, and CACS, but not with age or NT-proBNP (Table 2). There was no significant difference in hs-cTn-I concentrations among RA patients who were or were not currently receiving methotrexate, anti-TNF drugs, hydroxychloroquine, and corticosteroids (Table 3).

High Sensitivity cTn-I and Coronary Artery Calcification Score (CACS)
Although CACS was significantly correlated with hs-cTn-I concentrations in both patients with RA (rho = 0.33, P<0.001) and control subjects (rho = 0.24, P = 0.005), there were no statistically significant associations after multivariable model adjustment for age, race, sex and FRS in both RA (P = 0.79) and control subjects (P = 0.43).

Discussion
The major finding of this study was that concentrations of high sensitivity cardiac troponin-I, a biomarker of cardiac injury, were higher in patients with RA compared to controls. This difference in troponin-I concentrations between patients with RA and controls remained statistically significant after adjustment for demographic variables, inflammation, renal function, coronary artery disease, and cardiovascular risk factors.
As the preferred biomarkers of myocardial necrosis in patients suspected of having acute coronary syndrome (ACS), elevated cTn concentrations have almost complete specificity for myocardial tissue. Consensus guidelines recommend that cardiac troponin concentrations corresponding to the 99th percentile of a healthy population (commonly 0.03 μg/L or 30 pg/mL) be used as the threshold for defining an abnormal elevation [17–20]. More recently, high-sensitivity troponin assays allow measurement of troponin with detection limits 10-fold lower than conventional assays, and are thus capable of identifying subclinical myocardial injury and CV risk [12]. Low level hs-cTn elevation, is associated with increased risk of heart failure and cardiovascular death in patients with stable coronary artery disease [13]. Similarly, in several community-based studies, the troponin concentration detected was predictive of long-term cardiovascular outcomes [21,22]. For example, in the Atherosclerosis Risk in Communities (ARIC) cohort, cTn concentrations of 6–8 pg/mL were associated with significantly increased risk for coronary heart disease, heart failure, and mortality [22].

Patients with RA have shorter life expectancy, more ischemic heart disease and heart failure, and higher cardiovascular mortality compared to the general population [23,24,25]. The increased risk of heart failure in patients with RA is not explained by traditional cardiovascular risk factors, or solely by the presence of ischemic heart disease [8,26,27]. Interestingly, a recent cardiac MRI study reported lower myocardial mass in patients with RA compared to age matched controls [10], suggesting chronic Table 2. Correlation between hs-cTn-I and clinical variables in patients with RA and controls.

<table>
<thead>
<tr>
<th>Variable</th>
<th>RA Patients (n = 164)</th>
<th>Controls (n = 90)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.359</td>
<td>0.172</td>
</tr>
<tr>
<td>Age (linear P value)</td>
<td>&lt;0.001</td>
<td>0.104</td>
</tr>
<tr>
<td>Body mass index</td>
<td>−0.142</td>
<td>0.026</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>0.248</td>
<td>0.297</td>
</tr>
<tr>
<td>Systolic blood pressure P</td>
<td>0.001</td>
<td>0.005</td>
</tr>
<tr>
<td>Coronary calcium score</td>
<td>0.330</td>
<td>0.298</td>
</tr>
<tr>
<td>Coronary calcium score P</td>
<td>&lt;0.001</td>
<td>0.005</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>0.066</td>
<td>−0.056</td>
</tr>
<tr>
<td>HDL cholesterol P</td>
<td>0.402</td>
<td>0.605</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>0.174</td>
<td>0.154</td>
</tr>
<tr>
<td>LDL cholesterol P</td>
<td>0.027</td>
<td>0.15</td>
</tr>
<tr>
<td>Homocysteine</td>
<td>0.166</td>
<td>0.088</td>
</tr>
<tr>
<td>Homocysteine P</td>
<td>0.035</td>
<td>0.409</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.145</td>
<td>0.306</td>
</tr>
<tr>
<td>Creatinine P</td>
<td>0.064</td>
<td>0.003</td>
</tr>
<tr>
<td>TNFa</td>
<td>0.148</td>
<td>−0.106</td>
</tr>
<tr>
<td>TNFa P</td>
<td>0.061</td>
<td>0.321</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.093</td>
<td>−0.144</td>
</tr>
<tr>
<td>IL-6 P</td>
<td>0.243</td>
<td>0.188</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>−0.086</td>
<td>0.166</td>
</tr>
<tr>
<td>C-reactive protein P</td>
<td>0.275</td>
<td>0.119</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>0.255</td>
<td>0.062</td>
</tr>
<tr>
<td>NT-proBNP P</td>
<td>0.001</td>
<td>0.567</td>
</tr>
<tr>
<td>Disease Duration</td>
<td>0.197</td>
<td>N/A</td>
</tr>
<tr>
<td>Disease Duration P</td>
<td>0.012</td>
<td>N/A</td>
</tr>
<tr>
<td>DAS28</td>
<td>0.037</td>
<td>N/A</td>
</tr>
<tr>
<td>DAS28 P</td>
<td>0.638</td>
<td>N/A</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>−0.014</td>
<td>0.863</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate P</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*P values by Spearman’s correlation coefficient test.
doi:10.1371/journal.pone.0038930.t002

Table 3. Concentrations of hs-cTn-I in patients with RA receiving different drugs (n = 164).

<table>
<thead>
<tr>
<th>Current Drug Therapy</th>
<th>n</th>
<th>hs-cTn-I, pg/mL</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>On methotrexate</td>
<td>118</td>
<td>1.170 (0.732–1.802)</td>
<td>0.897</td>
</tr>
<tr>
<td>On methotrexate</td>
<td>46</td>
<td>1.08 (0.723–1.997)</td>
<td></td>
</tr>
<tr>
<td>Not on methotrexate</td>
<td>34</td>
<td>0.980 (0.750–1.627)</td>
<td>0.734</td>
</tr>
<tr>
<td>Not on anti-TNF drug</td>
<td>130</td>
<td>1.175 (0.723–1.952)</td>
<td></td>
</tr>
<tr>
<td>On hydroxychloroquine</td>
<td>42</td>
<td>1.095 (0.730–1.655)</td>
<td>0.428</td>
</tr>
<tr>
<td>Not on hydroxychloroquine</td>
<td>122</td>
<td>1.170 (0.732–1.927)</td>
<td></td>
</tr>
<tr>
<td>On corticosteroids</td>
<td>88</td>
<td>1.175 (0.737–1.942)</td>
<td>0.343</td>
</tr>
<tr>
<td>Not on corticosteroids</td>
<td>76</td>
<td>1.115 (0.728–1.787)</td>
<td></td>
</tr>
</tbody>
</table>

*Wilcoxon’s rank sum test.
doi:10.1371/journal.pone.0038930.t003
myocardial injury or myocardy loss as an underlying problem in RA. Our finding of increased circulating hs-cTnI would be concordant with that hypothesis.

The mechanistic explanation for elevated troponin concentrations in RA is not known. There are several proposed myocardial mechanisms for cTnI release, including subendocardial ischemia leading to myocyte necrosis, cardiomycocyte injury from inflammatory cytokines, hibernating myocardium, and apoptosis [28–32]. We found no significant association between hs-cTnI levels and inflammatory cytokines, acute phase reactants, or a disease activity score (Table 2). This suggests that active inflammation may not be the primary driver of troponin elevation in RA.

Viable cardiomycocytes, without necrosis, can release cTnI as an intact protein by a stretch-related mechanism mediated by integrins [33]. Thus, underlying hemodynamic stress leading to increased myocardial stretch may play a role in the elevated troponin concentrations in RA. The mechanism for BNP release from myocytes is also hypothesized to be stretch related. Indeed, we previously reported that NT-proBNP concentrations are elevated in patients with RA [9], and in the present study, hs-cTnI and NT-proBNP concentrations were significantly correlated. However, the concentrations of hs-cTnI remained significantly higher in patients with RA than controls, even when NT-proBNP was included in the statistical model. This suggests that there may be additional mechanisms underlying elevated hs-cTnI in RA, compared to those that drive NT-proBNP.

Patients with RA have an increased risk of ischemic heart disease. Thus, pre-existing heart disease could account for differences between RA patients and controls. Indeed, we found a significant correlation between hs-cTnI concentrations and CACS, a measure of coronary artery atherosclerosis. However, the association between hs-cTnI concentrations and CACS was not significant after adjustment for age, sex, race, and Framingham risk score. Furthermore, when we adjusted for cardiovascular risk factors, hs-cTnI concentrations remained significantly higher in patients with RA than controls.

These observations suggest that the clinical and subclinical measures of heart disease we studied do not fully account for the increased concentrations of hs-cTnI concentrations in RA patients. The most plausible explanation is that elevated hs-cTnI concentrations in RA patients reflect subclinical myocardial damage, perhaps reflected by small vessel disease or fibrosis, in addition to that accrued from hypertension, age, and other cardiovascular risk factors.

Another consideration is whether the increased concentrations of hs-cTnI in RA could be artifactual since rheumatoid factor and other heterophilic antibodies can potentially interfere with antibody-based immunoassays by nonspecific binding with detection agents. Rheumatoid factor, present in 71% of patients in this study, however, was not associated with higher circulating hs-cTnI.

Furthermore, in developing the assay, we designed the assay buffers to contain blockers to suppress interference from heterophilic antibodies, including RF and human anti-mouse antibodies. The assay was tested experimentally with samples known to contain high concentrations of such interfering substances and no interference was observed.

A limitation of the study was that we did not have measures of myocardial structure or function. Furthermore, the study was cross-sectional, and thus provided no information about long-term outcomes. We could not evaluate the temporal relationship between inflammatory markers and troponin. We cannot, for example, exclude the possibility that waxing and waning concentrations of inflammatory mediators during exacerbations of RA may affect hs-cTnI concentrations. The patients in this study had relatively well-controlled disease and it is possible that high levels of inflammation, as occurs in poorly controlled disease, may affect hs-cTnI concentrations.

In conclusion, high-sensitivity cTnI concentrations are elevated in patients with RA without heart failure, independent of cardiovascular risk profile and inflammatory markers. Elevated troponin concentrations in RA may indicate subclinical, indolent myocardial injury.

Author Contributions

Conceived and designed the experiments: WSB CMS. Performed the experiments: WSB AO JS, JE QAL JT. Analyzed the data: WSB CMS AB. Contributed reagents/materials/analysis tools: JE QAL JT. Wrote the paper: WSB CMS.

References


